Skip to Content

A123 Systems to Supply Plug-In Hybrid Batteries

Fisker Automotive has signed a supply agreement with the maker of nanostructured batteries.
January 14, 2010

Fisker Automotive, the startup that’s supposed to start delivering luxury plug-in hybrids later this year, has changed its battery supplier again. Now it’s going with A123 Systems, it announced today.

A123, which makes nanostructured lithium iron phosphate batteries that are safer and longer lasting than conventional lithium ion batteries, recently got a lot of money from a high-profile IPO. It’s also pulled in money from the feds to build battery factories. But it’s recently had bad news, too. It lost out to LG Chem for supplying batteries for the Chevrolet Volt (also due out this year). And then, after it announced an agreement to supply batteries for Chrysler, that automaker scaled back its plans for electric vehicles and plug in hybrids (cars that run mostly on electricity but have a gasoline engine for long trips). A123 also recently reported declining sales of batteries to the market it started with–cordless power tools.

Fisker had previously announced two other potential battery suppliers: Advanced Lithium Power, based in Vancouver, BC, and Enerdel, based in Indianapolis.

Keep Reading

Most Popular

open sourcing language models concept
open sourcing language models concept

Meta has built a massive new language AI—and it’s giving it away for free

Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3

transplant surgery
transplant surgery

The gene-edited pig heart given to a dying patient was infected with a pig virus

The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.

Muhammad bin Salman funds anti-aging research
Muhammad bin Salman funds anti-aging research

Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging

The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.

Yann LeCun
Yann LeCun

Yann LeCun has a bold new vision for the future of AI

One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.